Symbiotec Pharmalab Ltd (SYMBIOTEC) — Announcement | 28 September 2026

Symbiotec Pharmalab reported Q1 FY27 revenue of INR218 crores, up 7% YoY, driven by 6% growth in its core API business (INR215 crores). Gross margins held at 60%+ with API EBITDA at INR66 crores (+9% YoY). Consolidated EBITDA was INR45 crores and net profit INR14 crores, though new business investments created a temporary drag. Management highlighted strong customer loyalty (70% of FY26 revenue from clients with >7 year relationships) and defensibility in its steroid API business due to backward integration and regulatory approvals. The company emphasized its newly commissioned fermentation capacity (400 kL) as a foundation for future biotech CDMO and complex injectables growth, with multiple take-or-pay contracts already signed. Capital expenditure of INR68 crores was deployed in new facilities, with cumulative capex exceeding INR1,000 crores planned. Management targets 20-25% revenue and EBITDA growth for FY27 despite macro uncertainties.